Menu Search
Equities

Mesa Laboratories Inc

MLI:FRA

Mesa Laboratories Inc

Actions
  • Price (EUR)95.00
  • Today's Change2.50 / 2.70%
  • Shares traded5.00
  • 1 Year change+18.01%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:07 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. Its segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. It also provides testing and laboratory services, mainly to the dental and pharmaceutical industries. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services quality control products. It has manufacturing operations in the United States and Europe.

  • Revenue in USD (TTM)228.38m
  • Net income in USD-245.65m
  • Incorporated1982
  • Employees736.00
  • Location
    Mesa Laboratories Inc12100 W 6th AveLAKEWOOD 80228-1252United StatesUSA
  • Phone+1 (303) 987-8000
  • Fax+1 (303) 987-8989
  • Websitehttps://mesalabs.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.